For Ph-like acute lymphoblastic leukemia (ALL), tyrosine kinase inhibitors (TKIs) may be effective
the ONA take:
According to findings presented at the American Association for Cancer Research special conference Hematologic Malignancies: Translating Discoveries to Novel Therapies in Philadelphia, Pennsylvania, tyrosine kinase inhibitors (TKIs) may be effective for the treatment of children and young adults with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL).
Kathryn Roberts, PhD, postdoctoral research associate at St. Jude Children's Research Hospital in Memphis, Tennessee, and her colleagues recently described a type of B-cell ALL characterized by tyrosine kinase mutations associated with poor outcomes. This subtype of ALL is termed Ph-like ALL. The researchers introduced genetic mutations to tyrosine kinases in normal mouse blood cells and found that the cells developed Ph-like ALL. Then, the researchers grew human Ph-like ALL tumors in mice and treated them with dasatinib, a TKI, and observed decreased tumor burden in the mice. Furthermore, they found that the signal transducer and activator of transcription (STAT) signaling pathway associated with the genetic alterations involving tyrosine kinases was suppressed.
The researchers suggest that other TKIs approved by the U.S. Food and Drug Administration (FDA), such as crizotinib, imatinib, and ruxolitinib, could possibly be used to treat children and young adults with Ph-like ALL.
TKIs may be effective for the treatment of acute lymphoblastic leukemia.
Tyrosine kinase inhibitors (TKIs) may improve treatment outcome for children and young adults with Ph-like acute lymphoblastic leukemia (Ph-like ALL), a disease with dismal prognosis, according to data presented at the American Association for Cancer Research special conference Hematologic Malignancies: Translating Discoveries to Novel Therapies, held Sept. 20-23.
"We recently described a subtype of B-cell acute lymphoblastic leukemia with very poor outcome that is characterized by genetic alterations involving tyrosine kinases, termed Ph-like ALL," said Kathryn Roberts, PhD, postdoctoral research associate in the Department of Pathology at St. Jude Children's Research Hospital in Memphis, Tennessee. "We wanted to examine whether these alterations contribute to the development of Ph-like ALL, and determine if they could be targeted with tyrosine kinase inhibitors.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|